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EDITORIALAcrolein, a New Villain in the Development of Alcoholic
Liver Diseaselcoholic liver disease (ALD) is a consequence ofAchronic alcohol abuse. Alcoholic hepatitis (AH) and
alcoholic cirrhosis are 2 major disease forms that worsen
morbidity and mortality in patients with ALD. Approxi-
mately 35% of heavy alcohol drinkers develop AH and 40%
of severe AH patients die within 6 months; AH patients who
survive may progress to alcoholic cirrhosis. The treatment
for severe AH still largely is dependent on glucocorticoids
and pentoxifylline, as it has been for the past 40 years. In the
United States, approximately 45% of cirrhosis-related
deaths are caused by ALD and there are currently no ther-
apeutic agents for cirrhosis approved by the Food and Drug
Administration. Therefore, a better understanding of the
underlying molecular mechanisms of ALD and the devel-
opment of effective therapies would be highly clinically
relevant.
Liver is the major organ to metabolize alcohol. Alcohol is
converted by alcohol dehydrogenase to acetaldehyde, fol-
lowed by a breakdown to acetate through acetaldehyde
dehydrogenase. However, when alcohol intake exceeds the
capacity of alcohol dehydrogenase, excessive amounts of
alcohol are metabolized by cytochrome p4502E1, and this
alternative pathway generates reactive oxygen species
(ROS) in addition to acetaldehyde. Both ROS and acetalde-
hyde are highly hepatotoxic byproducts. ROS further in-
duces lipid peroxidation, which damages the liver. Previous
studies have shown that levels of dietary linoleic acid are
associated with the degree of liver injury in animal models
of alcoholic liver disease.1 Simultaneous treatment with
ethanol and corn oil enriched in linoleic acids results in
induction of high levels of hepatic cytochrome p4502E1,
increased lipid peroxidation, and resulting enhanced liver
injury. In addition to 4-hydroxynonenal and malondialde-
hyde, lipid peroxidation of polyunsaturated fatty acids such
as linoleic acids generates acrolein, a highly toxic byproduct.
In the current issue of Cellular and Molecular Gastroen-
terology and Hepatology, Chen et al2 provide new evidence
that acrolein, an unsaturated aldehyde, is generated and
accumulated in ALD and plays a signiﬁcant role in pro-
moting ALD through endoplasmic reticulum (ER) stress.
This study showed that acrolein and acrolein adducts
accumulate highly in the livers from alcohol-fed animals
in vivo and in hepatocytes exposed to ethanol and acetal-
dehyde in vitro. One of the key mechanisms of acrolein
accumulation the study proposes is through down-
regulation of glutathione-s-transferase-Pi, which normally
eliminates acrolein through glutathione conjugation. The
second important ﬁnding in this study was that hepatic ER
stress is associated with acrolein-mediated liver patho-
physiology in ALD. Heavy in vivo alcohol signiﬁcantlyCellular and Molecular Gastroenterology and Hepatology 2016;2:544–5up-regulated ER stress markers including activating tran-
scription factor 4 and CCAAT/enhancer-binding protein
homologous protein (CHOP), downstream of an ER stress
sensor protein kinase RNA-like endoplasmic reticulum
kinase, in the liver. Moreover, ER stress-mediated apoptotic
pathways were activated by processing procaspase-12 into
cleaved caspase-12. Activating transcription factor 4 and
CHOP up-regulation along with hepatocyte apoptosis also
was observed in hepatocytes exposed to ethanol and acet-
aldehyde in vitro. The essential role of acrolein in induction
of ER stress and hepatocyte damage was conﬁrmed by using
hydralazine, an established acrolein scavenger. Hydralazine
treatment markedly inhibited ethanol-mediated acrolein
induction and hepatocyte death. Impressively, hydralazine
treatment inhibited the expression of the ER stress marker
CHOP and the cleavage of the ER stress-mediated apoptotic
molecule caspase-12, which resulted in suppression of
alcohol-induced hepatocyte damage.
The study of acrolein in ALD has just begun. Acrolein
may affect a number of key pathophysiological pathways in
ALD in addition to ER stress pathways; the role of acrolein
in those pathways currently is unknown. What is the effect
of acrolein on lipid metabolism, ethanol metabolism, im-
mune systems, and ﬁbrosis in ALD? Targeting acrolein
therapeutically with hydralazine may be beneﬁcial, and the
drug has been used widely in patients with high blood
pressure. The need for administration of high doses, how-
ever, may limit its clinical use in ALD because of the un-
stable circulatory state of some AH patients. Future studies
testing alternate approaches to targeting acrolein offer
promise. For example, acrolein generation could be inhibi-
ted directly, or small molecules that complement
glutathione-s-transferase-Pi activity to inhibit acrolein
accumulation could be developed. The current study has
opened new doors in the study of unrecognized molecular
mechanisms of ALD and has provided insight into new
molecular targets for treating ALD.
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